Navigation Links
BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Date:10/3/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Oct. 3 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's U.S. pivotal phase III MAESTRO-03 trial of dirucotide (MBP8298) in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the third of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

About MAESTRO-03

----------------

The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized, double-blind study that has completed recruitment of approximately 510 patients at 68 clinical sites who will be administered either dirucotide (MBP8298) or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 75% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to announce that ... an e-Journal and producer of Food Labs Conference ... for the co-location of Food Labs Conference to be held ... registration fee to attend the two-day Food Lab Conference, March ...
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer health ... EmblemHealth , the New York -based ... RedBrick Compass health assessment, combined with the RedBrick Journeys ... EmblemHealth is among the first health plans in the ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains ... these latent viruses is the Epstein Barr Virus (EBV), and ... (RA) is a chronic inflammatory disease that destroys the body’s ... RA patients have high concentrations of EBV DNA in their ...
(Date:1/15/2014)... Biotechnology Company, Limited ("TaiGen") today announced that they have ... pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ® ... Turkey and other members of ... for the treatment of bacterial infections including those caused ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... MADISON - Life-saving science and cutting-edge business opportunities will ... and Venture Conference, to be held Nov. 3-5 at ... conference will be produced by three leading technology groups, ... the Wisconsin Innovation Network. , ,In the first full ...
... CA - With the children now back in school and a ... opportunity to demonstrate that the grownups have learned a few lessons ... next few weeks, a number of courageous souls will take their ... this time period than we did through the previous few months. ...
... MADISON, WI Governor Jim Doyle today announced his ... One of the recommendations is to increase broadband ... state. , ,Mike Tye, AT&T regional vice present ... is encouraged by the "Grow Wisconsin" initiative unveiled ...
Cached Biology Technology:Conference to Showcase Region's Biotech Companies 2The IPO Window Cracks 2
(Date:7/9/2014)... 2014) Emerging fungal pathogens pose a greater ... causing population declines of amphibians, bats, corals, bees ... South Florida published in the prestigious journal ... or immunological resistance to a deadly chytrid fungus ... "Acquired resistance is important because it is the ...
(Date:7/9/2014)... Atlas (TCGA) Research Network have identified novel mutations ... the most common subtype of lung cancer. Knowledge ... of possible therapeutic targets for this disease and ... treatable mutations because many potent cancer drugs that ... jointly funded and managed by the National Cancer ...
(Date:7/9/2014)... new study shows that some shark species may be able ... may come with rising temperatures. , The Arctic today is ... it wasn,t always like that. Roughly 53 to 38 million ... the Arctic was more similar to a huge temperate forest ... including ancestors of tapirs, hippo-like creatures, crocodiles and giant tortoises. ...
Breaking Biology News(10 mins):USF study: Amphibians can acquire resistance to deadly fungus 2Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... by humans to the natural landscapes can often compromise ... of crops by wild insects is one such vulnerable ... agricultural landscapes. The study, recently published in ... loss of wild insects impacts crop harvest. For this ...
... that regulates the reproduction of plants, providing a possible tool ... published today in Science , researchers from Monash University ... first time a particular gene that regulates the transition between ... John Bowman, of the Monash School of Biological Sciences said ...
... identify a novel signal transduction pathway, which activates ... death. Parkinson,s disease is the most common ... disease after Alzheimer,s disease. It is characterized by ... nigra, a region in the midbrain, which is ...
Cached Biology News:Wild pollinators increase crop fruit set regardless of honey bees 2Study provides insights into plant evolution 2Parkinson's disease: Parkin protects from neuronal cell death 2
Adhesive seal-tab, for HybriWell™ hybridization sealing system *set of 400*...
... choice of PDMS Stamps (3 PDMS micropatterned ... micron squares or 100 um x 10 ... lines, 3 PDMS nano-patterned stamps with depth ... pitch of 400 nm, or 3 PDMS ...
... contains 5 ml of DETACHaBEAD Mouse CD4, ... CD4+ T cells from Dynabeads Mouse CD4 ... T cells from Dynabeads Mouse CD4 using ... suitable for any downstream application including flow ...
Porcine IFN-gamma ELISpot Development Module...
Biology Products: